Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
US Department of Justice
McKesson
Farmers Insurance
Merck
Fuji
QuintilesIMS
Covington
Queensland Health

Generated: July 18, 2018

DrugPatentWatch Database Preview

EPTIFIBATIDE Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

Drug patent expirations by year for EPTIFIBATIDE
Pharmacology for EPTIFIBATIDE
Synonyms for EPTIFIBATIDE
[(3R,11S,17S,20S,25aS)-11-(4-carbamimidamidobutyl)-3-carbamoyl-20-(1H-indol-3-ylmethyl)-1,9,12,15,18,21-hexaoxodocosahydro-7H-pyrrolo[2,1-g][1,2,5,8,11,14,17,20]dithiahexaazacyclotricosin-17-yl]acetic acid
[22-Carbamoyl-14-(4-guanidino-butyl)-5-(1H-indol-3-ylmethyl)-4,7,10,13,16,24-hexaoxo-docosahydro-19,20-dithia-3a,6,9,12,15,23-hexaaza-cyclopentacyclotricosen-8-yl]-acetic acid (C68-22, eptifibatide)
148031-34-9
157630-07-4
17-yl)acetic acid
188627-80-7
2-((3R,11S,17S,20S,25aS)-20-((1H-indol-3-yl)methyl)-3-carbamoyl-11-(4-guanidinobutyl)-1,9,12,15,18,21-hexaoxodocosahydro-7H-pyrrolo[2,1-g][1,2]dithia[5,8,11,14,17,20]hexaazacyclotricosin-
2-((3R,11S,17S,20S,25aS)-20-((1H-indol-3-yl)methyl)-3-carbamoyl-11-(4-guanidinobutyl)-1,9,12,15,18,21-hexaoxodocosahydro-7H-pyrrolo[2,1-g][1,2]dithia[5,8,11,14,17,20]hexaazacyclotricosin-17-yl)acetic acid
2-[(3R,11S,17S,20S,25aS)-11-(4-carbamimidamidobutyl)-3-carbamoyl-20-(indol-3-ylmethyl)-1,9,12,15,18,21-hexaoxo-docosahydro-1H-pyrrolo[2,1-g]1,2-dithia-5,8,11,14,17,20-hexaazacyclotricosan-17-yl]acetic acid
2-[(3R,11S,17S,20S,25aS)-3-carbamoyl-11-{4-[(diaminomethylidene)amino]butyl}-20-[(1H-indol-3-yl)methyl]-1,9,12,15,18,21-hexaoxo-docosahydro-1H-pyrrolo[2,1-g]1,2-dithia-5,8,11,14,17,20-hexaazacyclotricosan-17-yl]acetic acid
2-[(3S,6S,12S,20R,23S)-20-carbamoyl-12-[4-(diaminomethylideneamino)butyl]-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,22-hexaoxo-17,18-dithia-1,4,7,10,13,21-hexazabicyclo[21.3.0]hexacosan-6-yl]acetic acid
31E349
ABP000579
AC1L9MDI
AKOS015895205
AKOS025147403
BC657177
BDBM50092098
C-23554
C35H49N11O9S2
C68-22
CAS-188627-80-7
CC-27500
CHEBI:291902
CHEMBL1174
CS-2925
CZKPOZZJODAYPZ-LROMGURASA-N
D09ZIO
DSSTox_CID_26673
DSSTox_GSID_46673
DSSTox_RID_81810
DTXSID7046673
eftifibatide
Eptifibatide [INN:BAN]
Eptifibatide Accord (generic)
Eptifibatide Acetate
Eptifibatide(Integrilin)/
GTPL6585
HS-2011
HSDB 8313
HY-B0686
Integrelin
Integrilin
Integrilin (TN)
Intrifiban
L-Cysteinamide, N6-(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophy-L-prolyl-, cyclic (1-6)-disulfide
L-Cysteinamide,N6-(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-|A-aspartyl-L-tryptophyl-L-prolyl-, cyclic (1 inverted exclamation marku6)-disulfide
L-Cysteinamide,N6-(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophy-L-propyl-,cyclic (1-6)-disulfide
LS-173318
MCULE-5698614065
MolPort-006-069-141
N(6)-amidino-N(2)-(3-mercaptopropionyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide, cyclic(1-6)-disulfide
N(sup 6)-Amidino-N(sup 2)-(3-mercaptopropionyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide, cyclic(1-6)-disulfide
NA8320J834
NCGC00167505-01
NCGC00263524-01
S(1),S(6)-cyclo[N(6)-carbamimidoyl-N(2)-(3-sulfanylpropanoyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide]
SB-1
Sch-60936
SCHEMBL15781
Tox21_112503
Tox21_112503_1
UNII-NA8320J834
V1343
Z2241982440
ZINC85536935

US Patents and Regulatory Information for EPTIFIBATIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Accord Hlthcare EPTIFIBATIDE eptifibatide INJECTABLE;INJECTION 205557-001 Nov 6, 2017 AP RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Aurobindo Pharma Ltd EPTIFIBATIDE eptifibatide INJECTABLE;INJECTION 206127-001 Dec 8, 2015 AP RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Akorn EPTIFIBATIDE eptifibatide INJECTABLE;INJECTION 204589-002 Apr 18, 2017 AP RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Teva Pharms Usa EPTIFIBATIDE eptifibatide INJECTABLE;INJECTION 091555-001 Jun 5, 2015 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
McKinsey
Cipla
Daiichi Sankyo
Merck
Argus Health
McKesson
Moodys
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.